Astex Pharmaceuticals (ASTX) Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator
7/8/2013 9:54:42 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DUBLIN, Calif., July 8, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced today its plan to submit an Investigational New Drug or IND application to the Food and Drug Administration (FDA) for ASTX727, a novel oral hypomethylating agent (HMA) in the fourth quarter of this year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by